human pc3 metastatic pca cell line (ATCC)
99
Structured Review
ATCC
human pc3 metastatic pca cell line

Human Pc3 Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 14852 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pc3/PC-3/pmc13106976-56-0-7
Average 99 stars, based on 14852 article reviews

Human Pc3 Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 14852 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pc3/PC-3/pmc13106976-56-0-7
Average 99 stars, based on 14852 article reviews
human pc3 metastatic pca cell line - by Bioz Stars,
2026-11
99/100 stars
Images
1) Product Images from "Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss"
Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss
Journal: Cell Reports Methods
doi: 10.1016/j.crmeth.2026.101370
Figure Legend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
Techniques Used: In Vivo, In Vitro, Concentration Assay
Related Articles
Cell Culture:Article Title: HDAC inhibition drives NOX5-dependent oxidative stress and sensitizes uveal melanoma cells to SOD1 inhibition. Article Snippet: Flasks were coated with an appropriate volume of a 2.5% (v/v) Matrigel working solution prepared by diluting high-concentration Matrigel (354248; BD Biosciences) in Ham's F-12 Nutrient Mix with L-glutamine (11765-047; Invitrogen) and supplemented with penicillinstreptomycin (100 U/mL). .. The Article Title: Electrospun Poly(lactide-co-glycolide-co-ε-caprolactone) as a Bioresorbable Platform for Docetaxel-Degradation, Drug Delivery Study and Anticancer Activity Article Snippet: Non-cancerous cells (the L-929 mouse subcutaneous fibroblast cell line, ATCC CCL-1 TM ) were cultured in ATCC-formulated Eagle’s Minimum Essential Medium (MEM). .. Article Title: FOXA1-driven ELOVL7 promotes lipid metabolic reprogramming and malignant progression in prostate cancer Article Snippet: Journal Pre-proof FOXA1-driven ELOVL7 promotes lipid metabolic reprogramming and malignant progression in prostate cancer Changheng Yang PII: S0040-8166(26)00813-X DOI: https://doi.org/10.1016/j.tice.2026.104117 Reference: YTICE104117 To appear in: Tissue and Cell Received date: 23 June 2026 Revised date: 15 October 2026 Accepted date: 1 November 2026 Please cite this article as: Changheng Yang, FOXA1-driven ELOVL7 promotes lipid metabolic reprogramming and malignant progression in prostate cancer, Tissue and Cell, (2026) doi:https://doi.org/10.1016/j.tice.2026.104117 This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. In Vitro:Article Title: Synthesis, cholinesterase inhibition, antiproliferative activity, and in silico evaluation of novel hydantoin conjugates Article Snippet: .. Three human cancer cell lines such as A549 (non-small cell lung cancer; American Type Culture Collection (ATCC), catalog no. CCL-185), Transfection:Article Title: FOXA1-driven ELOVL7 promotes lipid metabolic reprogramming and malignant progression in prostate cancer Article Snippet: Journal Pre-proof FOXA1-driven ELOVL7 promotes lipid metabolic reprogramming and malignant progression in prostate cancer Changheng Yang PII: S0040-8166(26)00813-X DOI: https://doi.org/10.1016/j.tice.2026.104117 Reference: YTICE104117 To appear in: Tissue and Cell Received date: 23 June 2026 Revised date: 15 October 2026 Accepted date: 1 November 2026 Please cite this article as: Changheng Yang, FOXA1-driven ELOVL7 promotes lipid metabolic reprogramming and malignant progression in prostate cancer, Tissue and Cell, (2026) doi:https://doi.org/10.1016/j.tice.2026.104117 This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Multiple Displacement Amplification:Article Title: Circulating FABP4 promotes obesity-associated breast cancer lung metastasis through PIP2. Article Snippet: Inc Cat# D12450J Dexamethasone MilliporeSigma Cat# D4902 Rosiglitazone MilliporeSigma Cat# R2408 IBMX MilliporeSigma Cat# I7018 Insulin MilliporeSigma Cat# I9278 FABP4 (human recombinant) FITC conjugated Cayman Cat# 9001068 MammoCultTM Human Medium Kit STEMCELL technologies Cat# 5620 Collagen I, rat tail ThermoFisher science Cat# A1048301 MitoSOXTM Mitochondrial Superoxide Indicators, for live-cell imaging (MitoSox Red) Invitrogen Cat# M36008 DCFDA/H2DCFDA - Cellular ROS Assay Kit Abcam Cat# ab113851 (Continued on next page) 18 Cell Reports ▪▪, 117788, ▪▪, 2026 Article ll OPEN ACCESS .. The cancer cell lines MDA-MB-231, E0771, 4T1, AU565, MCF7, Article Title: CDH3-directed immunotherapy targets basal-like hormone receptor negative prostate cancer and breast cancer. Article Snippet: .. DU145, 22Rv1, Tissue:Article Title: Genetic Variations in the Folate Regulatory Enzyme ALDH1L1: Impact on Cell Metabolism, Proliferation, and Motility Article Snippet: .. A549, DNA Profiling:Article Title: Genetic Variations in the Folate Regulatory Enzyme ALDH1L1: Impact on Cell Metabolism, Proliferation, and Motility Article Snippet: .. A549, Analysis:Article Title: Genetic Variations in the Folate Regulatory Enzyme ALDH1L1: Impact on Cell Metabolism, Proliferation, and Motility Article Snippet: .. A549, |